VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Stock Up 3.1 %

Shares of VNRX stock opened at $0.72 on Tuesday. The business has a 50 day moving average of $0.68 and a two-hundred day moving average of $0.68. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The company has a market cap of $65.86 million, a P/E ratio of -1.79 and a beta of 1.10.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.34 million. Analysts expect that VolitionRx will post -0.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Guy Archibald Innes bought 150,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were purchased at an average price of $0.67 per share, with a total value of $100,500.00. Following the completion of the acquisition, the director now directly owns 406,683 shares in the company, valued at approximately $272,477.61. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 12.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC raised its stake in VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.